CD28-Binding Antibodies for Targeted T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective antibodies that can specifically target and bind to CD28, a crucial protein on the surface of T cells, for therapeutic applications such as activating T cells or directing them to specific targets.
Innovation Solution
Development of antibodies, including multispecific antibodies, that are designed to bind to CD28 with specific CDR sequences, allowing for targeted activation and direction of T cells, as well as recombinant cells and compositions containing these antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibody technologies are used, then general T cell activation can be achieved, but specific targeting and binding to CD28 cannot be effectively accomplished
Solution Approach 1:
The patent applies local quality by designing antibodies with specifically engineered CDR regions that target only the CD28 protein on T cells. The variable regions (VH and VL) are configured with precise CDR sequences to bind locally and specifically to CD28, while the rest of the antibody structure provides standard immunoglobulin functions. This localized specificity resolution enables reliable CD28 targeting without compromising overall therapeutic effectiveness.
2Reliability
If multispecific antibodies are developed with specific CDR sequences, then specific CD28 binding is achieved, but antibody design and production complexity increases
Solution Approach 1:
The patent segments the antibody structure into distinct functional regions: variable heavy chain (VH) with CDR1-3, variable light chain (VL) with CDR1-3, and constant regions. Each CDR region is independently designed to contribute to CD28 binding specificity. This segmentation allows for modular design where the complexity is distributed across discrete functional units, making the multispecific antibody manageable despite its enhanced complexity.
Solution Approach 2:
The patent employs universality by designing the antibody framework to perform multiple functions simultaneously: the VH and VL regions bind to CD28 with high specificity, while the constant regions provide standard effector functions. The multispecific antibody can engage multiple targets (CD28 and potentially other antigens) through different binding sites, making the complex structure serve multiple therapeutic purposes rather than adding complexity for no reason.
Data Source
AI summary
Provided herein, in certain aspects, are antibodies that bind to CD28, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD28, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.